KRIBIOLISA Neutralizing Antibodies to Denosumab (PROLIA/XGEVA) ELISA includes features like:
– Ready to use protocol with break-apart wells for ease of use
– Standardisation and High Reproducibility
– Lot to Lot Consistency
– Accuracy and Precision
Validated against seven points for a ?GOLD RING? Standard Quality ELISA – the benchmark sign for Krishgen Quality. KRIBIOLISA ELISA kit is used for assessing the specific biomarker in samples analytes which may be human serum, plasma, biological fluids and cell culture supernatant. The kit uses indirect sandwich assay with double antibodies / recombinant proteins – capture and detection to ensure a high degree of sensitivity and specificity in the estimation of the analyte. Extensive validation has been done on these kits. Please ask for our validation guide if not availableon our product page. Incase you wish us to customize the kit, connect with us at sales1@krishgen.com
Background: The KRIBIOLISA ELISA kits are used for assessing the specific biomarker in samples analytes which may be serum and cell culture supernatant as validated with the kit. The kit employs a blocking ELISA technique which engages the blocking pathway to estimate the neutralizing antibodies. Denosumab is a fully synthetic monoclonal neutralizing antibody that acts as an IgG2 subclass immunoglobulin, inhibiting osteoclast differentiation, survival, and activity by competitively binding RANKL, thereby blocking RANK binding to RANKL. A neutralizing antibody (NAb) is an antibody that is responsible for defending cells from pathogens and are produced naturally by the body as part of its immune response. Their production is triggered by both infections and vaccinations against infections. In an immunogenetic context it will bind to a drug and neutralize its therapeutic effect.
Principle:
The method employs sandwich ELISA technique. The protein-protein interaction between HRP-RANKL and RNAK can be blocked by Denosumab. The neutralizing antibodies against Denosumab binds to Denosumab and thus a competitive inhibition is created. Samples and controls are pipetted in a blank microtitre plate and incubated with neutralizing antibody to Denosumab (NAb) and Denosumab. This complex of bound and unbound Denosumab is then incubated with HRP conjugated RANKL protein. The unbound Denosumab will bind to the HRP conjugated RANKL. The bound Nab-Denosumab will not bind to the HRP conjugated RANKL. This complex solution of bound antibodies to Denosumab and bound Denosumab to RANKL is then pipetted into RANK coated microplate. After washing, the substrate solution (TMB) is added to the microwells. Post incubation, color develops proportionate to the amount of bound RANKL. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!